A recent post here noted there were more billion-dollar deals than in years past, and the amount was higher than any other year. Along comes the Pfizer-Allergan deal at $160 billion, and we have revised the numbers upward. The key takeaways: 51 billion-dollar-plus deals in 2015 (4% of the 1,282 total), with $549.4 billion spent on those deals (90% of the current $549.4 billion). We’ll have more in the December issue of Health Care M&A News.